NKGN logo

NKGen Biotech Common Stock (NKGN) Financials

Balance sheets

30 June 202431 Mar 202431 Dec 202330 Sept 202330 June 202331 Mar 202331 Dec 202201 Sept 2022

Total Assets

$15.6 M(-4.1%)$16.3 M(-1.0%)$16.5 M(-34.6%)$25.2 M(+19.4%)$21.1 M-$16.3 M-

Current Assets

$1.2 M(-22.3%)$1.6 M(-16.7%)$1.9 M(-81.3%)$10.3 M(+400.2%)$2.1 M-$350.0 K-

Non Current Assets

$14.4 M(-2.1%)$14.7 M(+1.1%)$14.6 M(-2.0%)$14.8 M(-22.0%)$19.0 M-$16.0 M-

Total Liabilities

$85.4 M(+19.6%)$71.4 M(-5.1%)$75.2 M(+14.2%)$65.8 M(+96.8%)$33.5 M-$14.8 M-

Current Liabilities

$51.4 M(+37.1%)$37.5 M(-5.0%)$39.5 M(+1.6%)$38.8 M(+67.2%)$23.2 M-$14.7 M-

Long Term Liabilities

$34.0 M(+0.2%)$33.9 M(-5.1%)$35.7 M(+32.4%)$27.0 M(+163.8%)$10.2 M-$26.0 K-

Shareholders Equity

-$69.7 M(-26.6%)-$55.1 M(+6.2%)-$58.7 M(-44.4%)-$40.6 M(-228.9%)-$12.4 M-$1.6 M-

Book Value

-$69.7 M(-26.6%)-$55.1 M(+6.2%)-$58.7 M(-44.4%)-$40.6 M(-228.9%)-$12.4 M-$1.6 M-

Working Capital

-$50.2 M(-39.8%)-$35.9 M(+4.4%)-$37.5 M(-31.7%)-$28.5 M(-34.7%)-$21.2 M--$14.4 M-

Cash And Cash Equivalents

$79.0 K(+132.3%)$34.0 K(+30.8%)$26.0 K(-99.7%)$8.8 M(+619.0%)$1.2 M-$117.0 K-

Accounts Payable

$12.7 M(-1.1%)$12.8 M(+16.3%)$11.0 M(+39.1%)$7.9 M(+122.1%)$3.6 M-$975.0 K-

Accounts Receivable

--$0.0(0%)$0.0(0%)$0.0-$29.0 K-

Short Term Debt

$17.4 M(+48.7%)$11.7 M(+17.3%)$10.0 M(+87.5%)$5.3 M(-70.5%)$18.1 M-$12.0 M-

Long Term Debt

$10.7 M(+1.8%)$10.5 M(+5.7%)$9.9 M(-32.5%)$14.7 M(+44.1%)$10.2 M-$0.0-

Total Debt

$28.1 M(+26.6%)$22.2 M(+11.5%)$19.9 M(-0.6%)$20.0 M(-29.2%)$28.3 M(+100.0%)$0.0(-100.0%)$12.0 M(+100.0%)$0.0

Debt To Equity

-0.4(0%)-0.4(-17.6%)-0.3(+30.6%)-0.5(+78.6%)-2.3-7.7-

Current Ratio

0.0(-50.0%)0.0(-20.0%)0.1(-81.5%)0.3(+200.0%)0.1-0.0-

Quick Ratio

--------

Inventory

--------

Retained Earnings

-$183.6 M(-9.6%)-$167.5 M(-3.3%)-$162.1 M(-26.1%)-$128.5 M(-34.8%)-$95.3 M--$79.2 M-

PB Ratio

-0.5(+39.5%)-0.8(+26.9%)-1.0-----

Income statements

30 June 202431 Mar 202431 Dec 202330 Sept 202330 June 202331 Mar 202331 Dec 202201 Sept 2022

EPS

-$0.7(-168.0%)-$0.3(+85.1%)-$1.7(+32.3%)-$2.5(-591.6%)-$0.4(-40.5%)-$0.3(-19.8%)-$0.2(-3.8%)-$0.2

TTM EPS

-$5.1(-6.5%)-$4.8(+0.1%)-$4.8(-44.4%)-$3.3(-220.3%)-$1.0(-53.2%)-$0.7(-61.0%)-$0.4(-103.8%)-$0.2

Revenue

-------$3000.0

TTM Revenue

-------$3000.0

Total Expenses

$7.5 M(-2.1%)$7.6 M(-19.2%)$9.4 M(+36.6%)$6.9 M(+4.4%)$6.6 M(-2.8%)$6.8 M(+8.6%)$6.3 M(+4.4%)$6.0 M

Operating Expenses

$7.5 M(-2.1%)$7.6 M(-19.2%)$9.4 M(+36.6%)$6.9 M(+4.4%)$6.6 M(-2.8%)$6.8 M(+8.9%)$6.2 M(+4.2%)$6.0 M

Cost Of Goods Sold

------$15.0 K-

TTM Cost Of Goods Sold

------$15.0 K-

Gross Profit

--$0.0(0%)$0.0---$15.0 K(-600.0%)$3000.0

TTM Gross Profit

--$0.0(+100.0%)-$15.0 K---$12.0 K(-500.0%)$3000.0

Gross Margin

--------

Operating Profit

-$7.5 M(+2.1%)-$7.6 M(+19.2%)-$9.4 M(-36.6%)-$6.9 M(-4.4%)-$6.6 M(+2.8%)-$6.8 M(-8.6%)-$6.3 M(-4.5%)-$6.0 M

TTM Operating Profit

-$31.4 M(-2.8%)-$30.6 M(-2.8%)-$29.7 M(-11.9%)-$26.6 M(-3.5%)-$25.7 M(-34.7%)-$19.1 M(-55.5%)-$12.3 M(-104.5%)-$6.0 M

Operating Margin

--------199.7 K%

Net Income

-$16.1 M(-198.9%)-$5.4 M(+84.0%)-$33.6 M(-1.3%)-$33.2 M(-322.7%)-$7.8 M(+5.7%)-$8.3 M(-19.8%)-$6.9 M(-3.8%)-$6.7 M

TTM Net Income

-$88.3 M(-10.3%)-$80.0 M(+3.5%)-$83.0 M(-47.4%)-$56.3 M(-88.8%)-$29.8 M(-35.7%)-$22.0 M(-61.0%)-$13.6 M(-103.8%)-$6.7 M

Net Margin

--------223.1 K%

EBIT

-$15.4 M(-258.0%)-$4.3 M(+87.0%)-$33.2 M(-0.6%)-$33.0 M(-323.4%)-$7.8 M(+6.0%)-$8.3 M(-31.0%)-$6.3 M(-4.4%)-$6.1 M

TTM EBIT

-$85.9 M(-9.8%)-$78.2 M(+4.8%)-$82.2 M(-48.5%)-$55.4 M(-94.6%)-$28.5 M(-37.7%)-$20.7 M(-66.9%)-$12.4 M(-104.4%)-$6.1 M

EBITDA

-$15.1 M(-279.1%)-$4.0 M(+87.9%)-$32.9 M(-0.6%)-$32.7 M(-336.2%)-$7.5 M(+6.2%)-$8.0 M(-32.6%)-$6.0 M(+0.6%)-$6.1 M

TTM EBITDA

-$84.6 M(-9.9%)-$77.0 M(+4.9%)-$81.0 M(-49.6%)-$54.2 M(-96.6%)-$27.5 M(-37.3%)-$20.1 M(-66.1%)-$12.1 M(-99.4%)-$6.1 M

Selling, General & Administrative Expenses

$4.4 M(-0.3%)$4.4 M(-17.9%)$5.3 M(+79.6%)$3.0 M(+16.1%)$2.6 M(-19.9%)$3.2 M(+48.2%)$2.2 M(+15.2%)$1.9 M

TTM SG&A

$17.1 M(+11.8%)$15.3 M(+8.4%)$14.1 M(+29.2%)$10.9 M(+11.2%)$9.8 M(+35.4%)$7.2 M(+79.3%)$4.0 M(+115.2%)$1.9 M

Depreciation And Amortization

$326.0 K(0%)$326.0 K(+8.7%)$300.0 K(0%)$300.0 K(+0.3%)$299.0 K(-1.6%)$304.0 K-$904.0 K

TTM D&A

$1.3 M(+2.2%)$1.2 M(+1.8%)$1.2 M(+33.2%)$903.0 K(-40.1%)$1.5 M(+24.8%)$1.2 M-$904.0 K

Interest Expense

$647.0 K(-39.5%)$1.1 M(+144.1%)$438.0 K(+107.6%)$211.0 K(+240.3%)$62.0 K(+82.3%)$34.0 K(-94.5%)$616.0 K(-3.1%)$636.0 K

TTM Interest Expense

$2.4 M(+32.9%)$1.8 M(+138.9%)$745.0 K(-19.3%)$923.0 K(-31.5%)$1.3 M(+4.8%)$1.3 M(+2.7%)$1.3 M(+96.9%)$636.0 K

Income Tax

$0.0-$7000.0(+100.0%)$0.0(0%)$0.0-$7000.0(+100.0%)$0.0

TTM Income Tax

$7000.0-$7000.0(0%)$7000.0(0%)$7000.0-$7000.0(+100.0%)$0.0

PE Ratio

--------

PS Ratio

--------

Cashflow statements

30 June 202431 Mar 202431 Dec 202330 Sept 202330 June 202331 Mar 202331 Dec 202201 Sept 2022

Cash From Operations

-$6.0 M(-48.7%)-$4.0 M(+41.9%)-$6.9 M(-52.0%)-$4.6 M(+17.4%)-$5.5 M(-12.5%)-$4.9 M--$17.1 M

TTM CFO

-$21.5 M(-2.2%)-$21.1 M(+4.0%)-$21.9 M(-46.2%)-$15.0 M(+45.5%)-$27.5 M(-25.1%)-$22.0 M--$17.1 M

Cash From Investing

-$15.0 K(-142.9%)$35.0 K(+294.4%)-$18.0 K(-100.0%)$0.0(+100.0%)-$17.0 K(-30.8%)-$13.0 K--$158.0 K

TTM CFI

$2000.0(+100.0%)$0.0(+100.0%)-$48.0 K(-60.0%)-$30.0 K(+84.0%)-$188.0 K(-9.9%)-$171.0 K--$158.0 K

Cash From Financing

$6.1 M(+51.2%)$4.0 M(+322.2%)-$1.8 M(-114.9%)$12.1 M(+93.4%)$6.3 M(+12.8%)$5.6 M-$17.0 M

TTM CFF

$20.4 M(-1.0%)$20.6 M(-7.0%)$22.2 M(-7.5%)$24.0 M(-16.9%)$28.8 M(+27.8%)$22.5 M-$17.0 M

Free Cash Flow

-$6.0 M(-49.1%)-$4.0 M(+42.0%)-$7.0 M(-52.4%)-$4.6 M(+17.7%)-$5.5 M(-12.6%)-$4.9 M--$17.2 M

TTM FCF

-$21.6 M(-2.2%)-$21.1 M(+4.1%)-$22.0 M(-46.3%)-$15.0 M(+45.8%)-$27.7 M(-25.0%)-$22.2 M--$17.2 M

CAPEX

-------$158.0 K

TTM CAPEX

-------$158.0 K

Dividends Paid

--------

TTM Dividends Paid

--------

TTM Dividend Per Share

--------

TTM Dividend Yield

--------

Payout Ratio

--------